Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05900206
Title Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (ARIADNE)
Acronym ARIADNE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karolinska University Hospital
Indications
Therapies
Age Groups: adult | senior
Covered Countries SWE


No variant requirements are available.